# OnCo record serum-tumour-markers (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/serum-tumour-markers/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "serum-tumour-markers" ;
  schema:name "Serum tumour markers: proper use and misuse"@en ;
  schema:alternateName "tumour marker blood tests"@en, "CA-125"@en, "CEA"@en, "CA 19-9"@en, "PSA"@en, "AFP"@en, "LDH"@en, "beta-hCG"@en, "calcitonin"@en, "thyroglobulin"@en, "chromogranin A"@en, "CA 15-3"@en, "CA 72-4"@en, "HE4"@en, "SCC antigen"@en, "NSE"@en ;
  schema:description "The classic cancer blood tests, each a protein or hormone that some tumours pour into the blood; they are excellent for following a known cancer and useless or harmful as general screening, because nearly all of them are raised by common benign conditions too."@en ;
  schema:url <https://onco.cc/technologies/serum-tumour-markers/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(10)61268-8> ;
  onco:status "standard-of-care" ;
  onco:related <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/ideas/idea-tr2-biomarker-evidence-grading/> ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/testicular/>, <https://onco.cc/cancers/gestational-trophoblastic/>, <https://onco.cc/cancers/medullary-thyroid-cancer/>, <https://onco.cc/cancers/thyroid/>, <https://onco.cc/cancers/neuroendocrine/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/breast-cancer/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/germ-cell-tumour-markers/>, <https://onco.cc/technologies/thyroid-cancer-markers/>, <https://onco.cc/technologies/cea-surveillance-colorectal/>, <https://onco.cc/technologies/prostate-screening-psa-mri/>, <https://onco.cc/technologies/hcc-surveillance/>, <https://onco.cc/technologies/pancreatic-surveillance/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/mced/> ;
  onco:targets <https://onco.cc/targets/muc16/>, <https://onco.cc/targets/ceacam5/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/abbott/>, <https://onco.cc/companies/siemens-healthineers/>, <https://onco.cc/companies/beckman-coulter/>, <https://onco.cc/companies/fujirebio/> ;
  onco:terms <https://onco.cc/terms/tumour-marker/>, <https://onco.cc/terms/tumour-markers/>, <https://onco.cc/terms/ca-125/>, <https://onco.cc/terms/ca19-9/>, <https://onco.cc/terms/psa/>, <https://onco.cc/terms/afp/>, <https://onco.cc/terms/chromogranin-a/>, <https://onco.cc/terms/biomarker/>, <https://onco.cc/terms/biochemical-recurrence/>, <https://onco.cc/terms/psa50/>, <https://onco.cc/terms/ppv/>, <https://onco.cc/terms/sensitivity-specificity/>, <https://onco.cc/terms/overdiagnosis/> ;
  onco:trials <https://onco.cc/trials/ukctocs/> .